Skip to content

Sagimet Biosciences

US · SGMT #3599 by market cap Listed 2023
9.08 -0.54 -5.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:57

Price chart

Pre-market 9.30 -3.33%
After-hours 9.07 -0.11%
11.416.309.082026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SGMT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +7.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 17.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -1,537.0% Better than 2%
Net margin -1,393.8% Better than 2%
Return on equity -38.2% Better than 11%
Return on invested capital -42.6% Better than 7%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -11.4% Better than 47%
6-month return 28.1% Better than 89%
12-month return (ex latest month) 43.6% Better than 80%
Distance below 52-week high 20.7% Better than 59%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 22.8x Better than 99%
Debt to assets 0.1% Better than 99%
Interest coverage -221.8x Better than 3%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 91.7% Better than 75%
Upside to average target 204.8% Better than 95%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.15%
1M -6.78%
3M -10.81%
6M +36.54%
YTD +53.38%
1Y +24.90%
3Y +201.66%

Key statistics

Price & volume

Prev close
9.62
Open
9.32
Day range
8.83 - 9.40
Avg price
9.06
Volume
1.50M
Turnover
13.60M
Amplitude
5.90%
52-week range
4.50 - 11.45

Valuation

P/E
-5.75
P/E (TTM)
-7.69
P/B
2.68
EPS
-1.58
Net profit
-112.76M
Net assets
242.15M

Share structure

Market cap
648.02M
Float cap
543.85M
Shares out
71.37M
Float shares
59.90M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2023-07-14
52-week range 66% of range
4.50 11.45

20.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-4.34M net over the window

Short interest

Shares short
12.17M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Sagimet Biosciences (SGMT)?

Sagimet Biosciences last traded at 9.08. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Sagimet Biosciences's market cap?

About 648.02M.

What is the P/E ratio of Sagimet Biosciences?

The trailing twelve-month P/E is -7.69. The Valuation tab shows it against the stock's own five-year range.

Does Sagimet Biosciences pay a dividend?

Sagimet Biosciences does not currently pay a regular dividend.

Is Sagimet Biosciences a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 27.68, which implies 204.8% upside from the current price. This is not investment advice.

What is Sagimet Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Sagimet Biosciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:57:56 · For reference only, not investment advice and not tailored to your situation.

Sagimet Biosciences discussion 0 comments

Add a comment